 |
|
|
|
 |
|
|
 Kontakt |  Druckansicht |  PDF-Ansicht |  Firma weiterempfehlen
|
Medawar Centre, Robert Robinson Avenue, The Oxford Science Park
OX4 4GA Oxford
Großbritannien
|
|
Portrait
Oxford BioMedica is a biopharmaceutical company specializing in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Its lead product candidate is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialization. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin(R), a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.
Branchenbereiche
|
|
|
|
|
Top
